NCT01566526

Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 26 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.

Conditions

• Retinal Vein Occlusion
• Macular Oedema

Interventions

Type	Name	Description
DRUG	dexamethasone intravitreal implant 0.7 mg	OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.

Timeline

• Start date: 2012-03-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2012-03-29
• Last updated: 2013-05-27
• Results posted: 2013-05-27

Locations

1 site across 1 country: Belgium